Government Website Open Information Announcement

I. Authorization Method & Scope

In order to facilitate the public to betterutilize the website information, all of Centers for Disease Control (CDC)'spublicly posted information and materials that are protected under copyrightprovisions may be reauthorized for public use without cost in a non-exclusivemanner. The users are not limited to time and by region to reproduce, adapt,edit, publicly transmit or utilize with other methods, and as well as todevelop various products or services (herein known as derivations). Thisauthorization will not be retracted hereafter, and the users do not have toacquire any written or other methods of authorization from the Administration.However, when using it, the user should state the source.

II. Information on Related Items:

(a) The authorized scope is only within thescope protected under copyright. It does not include other intellectualproperty rights, including but not limited to the provision of patents,trademarks and administration’s logo.

(b) Whether or not the said person’sactively publicized or legally required publicized personal information can becollected, processed or utilized, the user must follow the related provisionsbased on the Personal Information Protection Act, and plan to execute therelated measures required by law.

(c) For some videos, photos, sheet musicand contracted case writings or other works, the administration must especiallystate that the approval must be duly obtained before use.

III. Should be prudential not to infringeupon a third party in moral rights in copyrights (including the rights toidentify names and the rights to ban unjustifiable change.)

IV. After using the information andmaterial provided by this authorization, one should not maliciously alter itsrelated information. If edited and the reworked information does not match theoriginal, the user is liable for civil and criminal legal responsibilities.

V. The website’s authorization does notauthorize the user to represent the administration’s recommendation, approvalor agreement with the status of the added derivatives.

UpdateTime 2019/4/11